(Q46117994)

19 December 2017

title

Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer (English)

1 reference

19 December 2017

main subject

phase II clinical trial

0 references

author

Gregory P. Kalemkerian

10

Gregory P Kalemkerian

1 reference

19 December 2017

Shirish M Gadgeel

3

Shirish M Gadgeel

1 reference

19 December 2017

Antoinette J Wozniak

8

Antoinette J Wozniak

1 reference

19 December 2017

Michael J Kraut

9

Michael J Kraut

1 reference

19 December 2017

author name string

Bryan J Schneider

1

1 reference

19 December 2017

Francis P Worden

2

1 reference

19 December 2017

Ralph E Parchment

4

1 reference

19 December 2017

Collette M Hodges

5

1 reference

19 December 2017

James Zwiebel

6

1 reference

19 December 2017

Rodney L Dunn

7

1 reference

19 December 2017

publication date

19 February 2009

1 reference

19 December 2017

Investigational New Drugs

published in

1 reference

19 December 2017

volume

27

1 reference

19 December 2017

issue

6

1 reference

19 December 2017

page(s)

571-578

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1007/s10637-009-9228-6

exact match

0 references

cites work

Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.

1 reference

12 December 2020

Ceramide signaling in fenretinide-induced endothelial cell apoptosis

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention

1 reference

12 December 2020

Phase II trial of fenretinide in advanced renal carcinoma

1 reference

12 December 2020

Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients

1 reference

12 December 2020

Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

Retinoids as preventive and therapeutic anticancer agents (Part I).

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid

1 reference

12 December 2020

Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations

1 reference

12 December 2020

Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.

1 reference

12 December 2020

Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer

1 reference

12 December 2020

Expression of nuclear retinoic acid receptors in normal tracheobronchial cells and in lung carcinoma cells

1 reference

12 December 2020

Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines.

1 reference

12 December 2020

Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study

1 reference

12 December 2020

Mechanisms of fenretinide-induced apoptosis

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.

1 reference

12 December 2020

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

1 reference

12 December 2020

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

12 December 2020

Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide: a Potent Inducer of Apoptosis in Human Neuroblastoma Cells

1 reference

12 December 2020

Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors

1 reference

12 December 2020

Multidisciplinary management of lung cancer

1 reference

12 December 2020

Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells

1 reference

12 December 2020

A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.

1 reference

12 December 2020

Induction of apoptosis by retinoids in human cervical-carcinoma cell-lines

1 reference

12 December 2020

Fenretinide activates a distinct apoptotic pathway

1 reference

12 December 2020

4-Hydroxyphenylretinamide in the chemoprevention of cancer

1 reference

12 December 2020

Human lung cancer cell lines exhibit resistance to retinoic acid treatment.

1 reference

12 December 2020

Cancer statistics, 2008

1 reference

12 December 2020

Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines

1 reference

12 December 2020

High frequency of retinoic acid receptor beta abnormalities in human lung cancer

1 reference

12 December 2020

Management of recurrent small cell lung cancer

1 reference

12 December 2020

10.1007/S10637-009-9228-6

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

19225720

1 reference

19 December 2017